Siemens Fonds Invest GmbH increased its position in shares of Pfizer Inc. (NYSE:PFE – Get Rating) by 0.2% during the first quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 222,935 shares of the biopharmaceutical company’s stock after buying an additional 354 shares during the quarter. Pfizer comprises about 0.9% of Siemens Fonds Invest GmbH’s portfolio, making the stock its 15th biggest position. Siemens Fonds Invest GmbH’s holdings in Pfizer were worth $11,541,000 at the end of the most recent reporting period.
A number of other institutional investors have also added to or reduced their stakes in the company. Cutter & CO Brokerage Inc. raised its stake in shares of Pfizer by 2.8% in the fourth quarter. Cutter & CO Brokerage Inc. now owns 13,029 shares of the biopharmaceutical company’s stock worth $769,000 after purchasing an additional 360 shares during the last quarter. Rational Advisors LLC purchased a new stake in shares of Pfizer in the fourth quarter worth approximately $1,041,000. Vaughan David Investments LLC IL raised its stake in shares of Pfizer by 17.7% in the fourth quarter. Vaughan David Investments LLC IL now owns 30,629 shares of the biopharmaceutical company’s stock worth $1,809,000 after purchasing an additional 4,596 shares during the last quarter. Associated Banc Corp raised its stake in shares of Pfizer by 1.2% in the fourth quarter. Associated Banc Corp now owns 306,965 shares of the biopharmaceutical company’s stock worth $18,126,000 after purchasing an additional 3,539 shares during the last quarter. Finally, Dakota Wealth Management raised its stake in shares of Pfizer by 5.3% in the fourth quarter. Dakota Wealth Management now owns 21,493 shares of the biopharmaceutical company’s stock worth $1,269,000 after purchasing an additional 1,085 shares during the last quarter. 67.90% of the stock is owned by institutional investors and hedge funds.
Analysts Set New Price Targets
Several brokerages have recently commented on PFE. JPMorgan Chase & Co. set a $57.00 price objective on Pfizer in a research note on Tuesday, June 28th. The Goldman Sachs Group set a $50.00 price target on Pfizer in a research report on Thursday, September 1st. SVB Leerink decreased their price target on Pfizer from $55.00 to $53.00 and set a “market perform” rating for the company in a research report on Friday, July 29th. Barclays set a $50.00 price target on Pfizer in a research report on Thursday, September 1st. Finally, UBS Group set a $59.00 price target on Pfizer in a research report on Thursday, September 1st. Nine investment analysts have rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Pfizer has an average rating of “Moderate Buy” and an average price target of $57.33.
Pfizer Price Performance
Pfizer (NYSE:PFE – Get Rating) last posted its quarterly earnings results on Thursday, July 28th. The biopharmaceutical company reported $2.04 EPS for the quarter, topping analysts’ consensus estimates of $1.95 by $0.09. Pfizer had a return on equity of 43.18% and a net margin of 28.92%. The firm had revenue of $27.74 billion during the quarter, compared to analyst estimates of $26.20 billion. During the same period last year, the company earned $1.07 earnings per share. The business’s revenue for the quarter was up 46.8% on a year-over-year basis. As a group, equities research analysts forecast that Pfizer Inc. will post 6.53 EPS for the current year.
Pfizer Announces Dividend
The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 6th. Investors of record on Wednesday, June 29th were paid a dividend of $0.40 per share. This represents a $1.60 annualized dividend and a yield of 3.34%. The ex-dividend date of this dividend was Thursday, July 28th. Pfizer’s dividend payout ratio is 31.31%.
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands.
- Get a free copy of the StockNews.com research report on Pfizer (PFE)
- MarketBeat: Week in Review 9/5 – 9/9
- Prepare For A Record-Setting Quarter For Cyber Security Stocks
- The Auto Market Is Slowly Recovering, These Stocks May Outperform
- Is DocuSign On The Verge Of A Major Reversal?
- Oil and Gas Stocks: A Safe Way to Invest in Renewable Energy
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.